Recently, promising results have been obtained with the use of checkpoint inhibitors in lymphomas; in particular, lymphomas characterized by immune escape of the tumor cells are considered good candidates for anti-PD-1/PD-L1 therapy [45,46,47]. Here, CD274 is linked to neoplasm.